Skip to main content

Contact us for your consultation (706) 250-1960

Following findings that eight patients experienced significant, non-life threatening heart incidents, Teva Pharmaceutical Industries Ltd. And Active Biotech AB have ceased phase-2 and phase-3 clinical trial studies of Laquinimod.  Laquinimod is used for the treatment of multiple sclerosis and Huntington Disease. The U.S. Food and Drug Administration (FDA) requires phase 3 clinical trial completion before a drug can obtain approval for distribution on a large scale.

These heart-related incidents occurred after high doses of the drug were administered as part of the Bravo (Phase-2) and Concerto (Phase-3) phases of the study. Both companies have stated that only low-dose and placebo components of the study phases will continue moving forward.

The study includes 2,199 patients and was set for completion after 24-months of use or the reports of 260 significant health-related events. The dosage responsible for the significant cardiovascular events is the 1.2mg/day dosage.

If you or someone you know has been experienced a significant heart-related event during the Bravo or Concerto phases of these studies, due to the use of Laquinimod, contact Harman Law, at 1-888-55-HARMAN, to discuss potential legal recourse and possible monetary compensation. At Harman Law, the initial consultation comes at no cost to you.

Posted on behalf of Harman Law Firm

Contact Us


    Harman Law Firm

    4.8 / 5.0

    Based on 23 reviews


    Matt has been a warrior during our long and difficult battle for justice.


    After my grandparents were victims of fraud, Matt fought for their rights.

    Denise B.

    When my child died because of gross negligence, the Harman Law Firm got justice for his memory.


    3575 Piedmont Road NE Bldg 15, Suite 1040
    Atlanta, GA, 30305
    Phone: (404) 554-0777

    Free consultation


    3540 Wheeler Rd #603
    Augusta, GA, 30909
    Phone: (706) 250-1960

    Free consultation